Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Types of RNA01:20

Types of RNA

6.3K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
6.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Cardiovascular research·2025
Same author

An interplay of non-coding RNAs regulates <i>CDH13</i> expression and affects endothelial function and coronary artery disease risk.

Research square·2025
Same author

Aging-regulated PNUTS maintains endothelial barrier function via SEMA3B suppression.

Communications biology·2024
Same author

DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.

Journal of cell science·2024
Same author

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice.

iScience·2024

相关实验视频

Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K

长非编码RNA治疗心血管疾病

Noelia Bellon Quinones1,2, Ruggero Belluomo3,4, Rio P Juni5,6

  • 1Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University, Frankfurt Am Main, Germany.

Journal of cardiovascular translational research
|September 3, 2025
PubMed
概括

长非编码RNAs (lncRNAs) 是心血管疾病 (CVD) 的关键调节剂. 研究强调它们作为生物标志物和治疗点的潜力,先进的基因疗法显示出未来治疗的前景.

关键词:
心血管疾病基因治疗长非编码RNAs (lncRNAs)对于RNA疗法

更多相关视频

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

相关实验视频

Last Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

科学领域:

  • 分子生物学
  • 心血管研究
  • 遗传学

背景情况:

  • 心血管疾病 (CVD) 是全球的主要健康问题,促使人们需要新的治疗方法.
  • 长非编码RNAs (lncRNAs) 越来越多地被认为是细胞过程中与心血管健康和疾病相关的基因表达的关键调节者.

研究的目的:

  • 审查 lncRNAs 在心血管疾病的发病过程中的功能作用.
  • 探索 lncRNAs 作为诊断生物标志物和治疗点的潜力.
  • 讨论基因治疗的进展和基于 lncRNA 的心血管治疗策略.

主要方法:

  • 对心血管疾病中的IncRNA功能的文献综述.
  • 分析当前的RNA向技术 (例如反意义寡核酸,siRNAs,CRISPR).
  • 对 lncRNA 疗法的病毒和非病毒传递系统的评估.

主要成果:

  • lncRNAs涉及至关重要的心血管疾病过程,包括缩,纤维化,炎症和血管重塑.
  • 新兴的RNA向技术为心血管疾病提供了潜在的治疗途径.
  • 基于 lncRNA 的疗法在临床转化方面仍然存在挑战,特别是在传递方法方面.

结论:

  • 对于心血管疾病的新诊断和治疗策略来说, lncRNA 是一个有前途的领域.
  • 进一步研究 lncRNA 生物学和传递系统的优化对于临床应用至关重要.
  • 基于 lncRNA 的疗法有可能显著提高心血管医学.